Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer

Fineline Cube May 26, 2025

China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...

Company Drug

Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial

Fineline Cube May 26, 2025

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...

Company Drug

GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma

Fineline Cube May 26, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...

Company Drug

Dizal Pharma Presents DZD8586 and DZD6008 Results at ASCO 2025

Fineline Cube May 26, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical results for its investigational...

Company Drug

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Breakthrough Therapy Designation for HCC

Fineline Cube May 26, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that it has received Breakthrough Therapy...

Company Deals

Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline

Fineline Cube May 26, 2025

China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong...

Company Deals

Medilink Therapeutics Collaborates with Wuhan Union Hospital on Clinical Trials

Fineline Cube May 26, 2025

Suzhou-based Medilink Therapeutics announced a clinical study collaboration agreement with Union Hospital, Tongji Medical College,...

Company Drug

Duality Biologics Receives FDA IND Approval for EGFR/HER3 ADC AVZO-1418

Fineline Cube May 26, 2025

Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United...

Company Drug

Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial

Fineline Cube May 26, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from...

Company Drug

Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals

Fineline Cube May 26, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody

Fineline Cube May 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...

Company Drug

Roche’s Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its Itovebi (inavolisib) has been...

Company Medical Device

Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study

Fineline Cube May 26, 2025

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company Deals

Roche Partners with Broad Clinical Labs to Advance SBX Sequencing Technology

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced last week a strategic partnership with...

Company Drug

Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis

Fineline Cube May 26, 2025

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...

Company Medical Device

Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications

Fineline Cube May 26, 2025

US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)...

Company Deals

Tonghua Dongbao to Sell Stake in Amoytop Biotech for USD 181 Million

Fineline Cube May 24, 2025

Chinese pharmaceutical firm Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) has announced plans to divest...

Company Deals

Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation

Fineline Cube May 24, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...

Company Deals

PacBio Appoints Haorui Gene as Official Distributor in China

Fineline Cube May 24, 2025

US-based sequencing solutions provider PacBio (NASDAQ: PACB) has appointed China’s Haorui Gene as an official...

Company Drug

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Fineline Cube May 23, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...

Posts pagination

1 … 90 91 92 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.